Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice

Neuron

Volumn 19, Issue 1, 1997, Pages 103-113

  Kelly, Michele A ^a   Rubinstein, Marcelo ^a,d   Asa, Sylvia L ^b   Zhang, Ge ^a   Saez, Carmen ^a   Bunzow, James R ^a   Allen, Richard G ^a   Hnasko, Robert ^c   Ben Jonathan, Nira ^c   Grandy, David K ^a   Low, Malcolm J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d INSTITUTO DE INVESTIGACIONES EN INGENIERÍA GENÉTICA Y BIOLOGÍA MOLECULAR   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; DOPAMINE 2 RECEPTOR; ESTROGEN; PROLACTIN;

ADENOMYOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CELL HYPERPLASIA; CONTROLLED STUDY; DOPAMINE RELEASE; EMBRYO; GENE DISRUPTION; HYPERPROLACTINEMIA; HYPOPHYSIS INTERMEDIATE LOBE; HYPOTHALAMUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROLACTIN RELEASE; PROLACTIN SECRETING CELL; RECEPTOR GENE; SIGNAL TRANSDUCTION;

EID: 0030838736     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6273(00)80351-7     Document Type: Article

References (54)

1. Asa, S.L., Penz, G., Kovacs, K., and Ezrin, C. (1982). Prolactin cells in the human pituitary. A quantitative immunocytochemical analysis. Arch. Pathol. Lab. Med. 106, 360-363.
2. Asa, S.L., Kovacs, K., Stefaneanu, L., Horvath, E., Billestrup, N., Gonzalez-Manchon, C., and Vale, W. (1990). Pituitary mammosomatotroph adenomas develop in old mice transgenic for growth hormone-releasing hormone. Proc. Soc. Exp. Biol. Med. 193, 232-235.
3. Asa, S.L., Kovacs, K., Stefaneanu, L., Horvath, E., Billestrup, N., Gonzalez-Manchon, C., and Vale, W. (1992). Pituitary adenomas in mice transgenic for growth hormone-releasing hormone. Endocrinology 131, 2083-2089.
4. Baik, J.H., Picetti, R., Salardii, A., Thirlet, G., Dierich, A., Depaulis, A., Le Meur, M., and Borrelli, E. (1995). Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 377, 424-428.
5. Ben-Jonathan, N., Mershon, J.L., Allen, R.W., and Steinmetz, R.W. (1996). Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocrine Rev. 17, 639-669.
6. Borrelli, E., Sawchenko, P.E., and Evans, R.M. (1992). Pituitary hyperplasia induced by ectopic expression of nerve growth factor. Proc. Natl. Acad. Sci. USA 89, 2764-2768.
7. Bunzow, J.R., Van Tol, H.H.M., Grandy, D.K., Albert, P., Salon, J., Christie, M., Machida, C.A., Neve, K.A., and Civelli, O. (1988). Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 336, 783-787.
8. Bunzow, J.R., Zhang, G., Bouvier, C., Saez, C., Ronnekleiv, O.K., Kelly, M.J., and Grandy, D.K. (1995). Characterization and distribution of a cloned rat μ-opioid receptor. J. Neurochem. 64, 14-24.
9. Caccavelli, L., Cussac, D., Pellegrini, I., Audinot, V., Jaquet, P., and Enjalbert, A. (1992). D2 dopaminergic receptors: normal and abnormal transduction mechanisms. Horm. Res. 38, 78-83.
10. 3H] thymidine uptake measurement. Endocrinology 120, 1201-1211.
11. Chronwall, B.M., Hook, G.R., and Millington, W.R. (1988). Dopaminergic regulation of the biosynthetic activity of individual melanotropes in the rat pituitary intermediate lobe: a morphometric analysis by light and electron microscopy and in situ hybridization. Endocrinology 123, 1992-2002.
12. Civelli, O., Bunzow, J.R., and Grandy, D.K., (1993). Molecular diversity of the dopamine receptors. Annu. Rev. Pharmacol. Toxicol. 32, 281-307.
13. Cote, I.E., Eskay, R.L., Frey, E.A., Grewe, C.W., Munemura, M., Stoof, J.C., Tsututa, K., Kebabian, J.W. (1982). Biochemical and physiological studies of the beta-adrenoceptor and the D2 dopamine receptor in the intermediate lobe of the rat pituitary gland: a review. Neuroendocrinology 35, 217-224.
14. Da Silva, L., Howard, O.M.Z., Rui, H., Kirken, R.A. and Farrar, W.L. (1994). Growth signaling and JAK2 association mediated by membrane-proximal cytoplasmic regions of prolactin receptors. J. Biol. Chem. 269, 18267-18270.
15. Davis, M.D., Lichtensteiger, W., Schlumpf, M., and Bruinink, A. (1984). Early postnatal development of pituitary intermediate lobe control in the rat by dopamine neurons. Neuroendocrinology 39, 1-12.
16. Doetschman, T.C., Eistetter, H., Katz, M., Schmidt, W., and Kemler, R. (1985). The in vitro development of blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium. J. Embryol. Exp. Morphol. 87, 27-45.
17. Doppler, W. (1994). Regulation of gene expression by prolactin. Rev. Physiol. Biochem. Pharmacol. 124, 93-130.
18. Fero, M.L., Rivkin, M., Tasch, M., Porter, P., Carow, C.E., Firpo, E., Polyak, K., Tsai, L.H., Broudy, V., Perlmutter, R.M., Kaushansky, K., and Roberts, J.M. (1996). A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85, 733-744.
19. Florio, T., Pan, M.-G., Newman, B., Hershberger, R.E., Civelli, O., and Stork, P.J.S. (1992). Dopaminergic inhibition of DNA synthesis in pituitary tumor cells is associated with phosphotyrosine phosphatase activity. J. Biol. Chem. 267, 24169-24172.
20. Gingrich, J.A., and Caron, M.G. (1993). Recent advances in the molecular biology of dopamine receptors. Annu. Rev. Neurosci. 16, 299-321.
21. Hollt, V., Haarmann, I., Seizinger, B.R., and Herz, A. (1982). Chronic haloperidol treatment increases the level of in vitro translatable messenger ribonucleic acid coding for the β-endorphin/adrenocorticotrophin precursor proopiomelanocortin in the pars intermedia of the rat pituitary. Endocrinology 110, 1885-1891.
22. Horvath E. (1988). Pituitary hyperplasia. Pathol. Res. Pract. 183, 623-625.
23. Hu, N., Gutsmann, A., Herbert, D.C., Bradley, A., Lee, W.H., and Lee, E.Y. (1994). Heterozygous Rb-1 delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 9, 1021-1027.
24. Husby, R.A., and Thurlow, S. (1982). Effects of prenatal exposure of mice to "low-dose" diethylstilbestrol and the development of adenomyosis associated with evidence of hyperprolactinemia. Am. J. Obstet. Gynecol. 144, 939-949.
25. Husby, R.A., Soares, M.J., and Talamantes, F. (1985). Ectopic pituitary grafts in mice: hormone levels, effects on fertility, and the development of adenomyosis uteri, prolactinomas, and mammary carcinomas. Endocrinology 116, 1440-1448.
26. Jay, V., Kovacs, K., Horvath, E., Lloyd, R.V., and Smyth, H.S. (1991). Idiopathic prolactin cell hyperplasia of the pituitary mimicking prolactin cell adenoma: a morphological study including immunocytochemistry, electron microscopy and in situ hybridization. Acta Neuropath. (Berl.) 82, 147-151.
27. Jung, Y., and Russfield, A.B. (1972). Prolactin cells in the hypophysis of cirrhotic patients. Arch. Pathol. 94, 265-269.
28. Kiino, D.R., and Dannies, P.S. (1981). Insulin and 17β-estradiol increase the intracellular prolactin content of GH4C1 cells. Endocrinology 109, 1264-1269.
29. Kovacs, K., Horvath, E., Asa, S.L., Murray, D., Singer, W., and Reddy, S.S.K. (1986). Microscopic peliosis of pancreatic islets in a woman with MEN-1 syndrome. Arch. Pathol. Lab. Med. 110, 607-610.
30. Liu, X., Robinson, G.W., Wagner, K.-U., Garrett, L., Wynshaw-Boris, A., and Hennighausen, L. (1997). Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 11, 179-186.
31. Lloyd, H.M., Meares, J.D., and Jacobi, J. (1975). Effects of oestrogen and bromocryptine on in vivo secretion and mitosis in prolactin cells. Nature 255, 497-498.
32. Low, M.J., Liu, B., Hammer, G.D., Rubinstein, M., and Allen, R.G. (1993). Post-translational processing of proopiomelanocortin (POMC)in mouse pituitary melanotroph tumors induced by a POMC-simian virus 40 largeTantigen transgene. J. Biol. Chem. 265, 24967-24975.
33. McAndrew, J., Paterson, A.J., Asa, S.L., McCarthy, K.J., and Kudlow, J.E. (1995). Targeting of transforming growth factor-α expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas. Endocrinology 136, 4479-4488.
34. Meador-Woodruff, J.H., Pellerito, B., Bronstein, D., Lin, H.L., Ling, N., and Akil, H. (1990). Differential effects of haloperidol on the rat pituitary: decreased biosynthesis, processing and release of anterior lobe pro-opiomelanocortin. Neuroendocrinology 51, 294-303.
35. Meller, E., Puza, T., Miller, J.C., Friedhoff, A.J., and Schweitzer, J.W. (1991). Receptor reserve for D2 dopaminergic inhibition of prolactin release in vivo and in vitro. J. Pharmacol. Exp. Ther. 257, 668-674.
36. 3H] thymidine into rat pituitary tumor cells. Brain Res. 369, 83-90.
37. Molitch, M.E. (1995). Prolactin. In The Pituitary, S. Melmed, ed. (Cambridge: Blackwell Science), pp. 146-159.
38. Morel, G., Ouhtit, A., and Kelly, P.A. (1994). Prolactin receptor immunoreactivity in rat anterior pituitary. Neuroendocrinology 59, 78-84.
39. Ormandy, C.J., Camus, A., Barra, J., Damotte, D., Lucas, B., Buteau, H., Edery, M., Brousse, N., Babinet, C., Binart, N., and Kelly, P.A. (1997). Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev. 11, 167-178.
40. Ort h, D.N., Kovacs, W.J., and Debold, C.R. (1992). The adrenal cortex. In Williams Textbook of Endocrinology, J.D. Wilson and D.W. Foster, eds., Eighth Edition (Philadelphia: W.B. Saunders Co.), pp. 489-619.
41. Peillon, F., Dupuy, M., and Li, J.Y. (1991). Pituitary enlargement with suprasellar extension in functional hyperprolactinemia due to lactotroph hyperplasia: a pseudotumoral disease. J. Clin. Endocrinol. Metab. 73, 1008-1015.
42. Phelps, C., and Hymer, W.C. (1983). Characterization of estrogen-induced adenohypophyseal tumors in the Fischer 344 rat. Neuroendocrinology 37, 23-31.
43. Rubinstein, M., Mogil, J.S., Japon, M., Chan, E.C., Allen, R.G., and Low, M.J. (1996). Absence of opioid stress-induced analgesia in mice lacking β-endorphin by site-directed mutagenesis. Proc. Natl. Acad. Sci. USA 93, 3995-4000.
44. Scheithauer, B.W., Kovacs, K., Randall, R.V., and Ryan, N. (1989). Effects of estrogen on the human pituitary: a clinicopathologic study. Mayo Clin. Proc. 64, 1077-1084.
45. Scheithauer, B.W., Sano, T., Kovacs, K.T., Young, W.F., Jr., Ryan, N., and Randall, R.V. (1990). The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin. Proc. 65, 461-74.
46. Seeman, P., and Van Tol, H.H.M. (1994). Dopamine receptor pharmacology. Trends Pharmacol. Sci. 15, 264-270.
47. Sibley, D.R., and Creese, I. (1983). Interactions of ergot alkaloids with anterior pituitary D2 dopamine receptors. Mol. Pharmacol. 23, 585-593.
48. Sibley, D.R., Monsma, F.J., and Shen, Y. (1993). Molecular neurobiology of dopaminergic receptors. Int. Rev. Neurobiol. 35, 391-415.
49. Singtripop, T., Mori, T., Park, M.K., Sakamoto, S., and Kawashima, S. (1991). Development of uterine adenomyosis after treatment with dopamine antagonists in mice. Life Sci. 49, 201-206.
50. Steinmetz, R., Brown, N.G., Allen, D.L., Bigsby, R.M., and Ben-Jonathan, N. (1997). The environmental estrogen bisphenol A stimulates prolactin release in vitro and in vivo. Endocrinology 138, 1780-1786.
51. Van Biesen, T., Luttrell, L.M., Hawes, B.E., and Lefkowitz, R.J. (1996). Mitogenic signaling via G protein-coupled receptors. Endocr. Rev. 17, 698-714.
52. Wass, J.A.H., Williams, J., Charlesworth, M., Kingsley, D.P.E., Halliday, A.M., Doniach, I., Rees, L.H., McDonald, W.I., and Besser, G.M. (1982). Bromocriptine in management of large pituitary tumors. Br. Med. J. 284, 1908-1911.
53. Williams, B.O., Schmitt, E.M., Remington, L., Bronson, R.T., Albert, D.M., Weinberg, R.A., and Jacks, T. (1994). Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences. EMBO J. 13, 4251-4259.
54. Zhang, G., Lagrange, A.H., Ronnekleiv, O.K., and Kelly, M.J. (1996). Tolerance of hypothalamic β-endorphin neurons to μ-opioid receptor activation following chronic morphine treatment. J. Pharmacol. Exp. Ther. 277, 551-558.